Last10K.com

Zoetis Inc. (ZTS) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

SEC Filings

ZTS Annual Reports

  • 10-K Annual Report February 2022
  • 10-K Annual Report February 2021
    10-K Annual Report February 2020
    10-K Annual Report February 2019
    10-K Annual Report February 2018
    10-K Annual Report February 2017
    10-K Annual Report February 2016
    10-K Annual Report February 2015
    10-K Annual Report March 2014

Zoetis Inc.

CIK: 1555280 Ticker: ZTS




EXHIBIT 99.1

zoetisca04a01a01a01a01a18a.jpg



Zoetis Reports Fourth Quarter and Full Year 2021 Results

For Fourth Quarter 2021, Zoetis Reports Revenue of $2.0 Billion, Growing 9%, and Net Income of $414 Million, or $0.87 per Diluted Share, on a Reported Basis
Reports Adjusted Net Income of $474 Million, or Adjusted Diluted EPS of $1.00, for Fourth Quarter 2021
Delivers 9% Operational Growth in Revenue and 5% Operational Growth in Adjusted Net Income for Fourth Quarter 2021
For Full Year 2021, Zoetis Reports Revenue of $7.8 Billion, Growing 16%, and Net Income of $2.0 Billion, or $4.27 per Diluted Share, on a Reported Basis
Reports Adjusted Net Income of $2.2 Billion, or Adjusted Diluted EPS of $4.70 for Full Year 2021
Delivers 15% Operational Growth in Revenue and 19% Operational Growth in Adjusted Net Income for Full Year 2021
Provides Full Year 2022 Revenue Guidance of $8.325 - $8.475 Billion, with Diluted EPS of $4.75 to $4.87 on a Reported Basis, or $5.09 to $5.19 on an Adjusted Basis


PARSIPPANY, N.J. - Feb. 15, 2022 - Zoetis Inc. (NYSE: ZTS) today reported its financial results for the fourth quarter and full year 2021 and provided full year guidance for 2022.

The company reported revenue of $2.0 billion for the fourth quarter of 2021, which was an increase of 9% compared with the fourth quarter of 2020. Net income for the fourth quarter of 2021 was $414 million, or $0.87 per diluted share, an increase of 15% and 16%, respectively, on a reported basis.

Adjusted net income1 for the fourth quarter of 2021 was $474 million, or $1.00 per diluted share, an increase of 8% and 10%, respectively, on a reported basis. Adjusted net income for the fourth quarter of 2021 excludes the net impact of $60 million for purchase accounting adjustments, acquisition-related costs and certain significant items.

On an operational2 basis, revenue for the fourth quarter of 2021 increased 9% compared with the fourth quarter of 2020, with no impact from foreign exchange. Adjusted net income for the fourth quarter of 2021 increased 5% operationally, excluding the impact from foreign exchange.

1 |


The following information was filed by Zoetis Inc. (ZTS) on Tuesday, February 15, 2022 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Zoetis Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Zoetis Inc..

Continue

Assess how Zoetis Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Zoetis Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Audit Information
Cover
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive Income
Consolidated Statements Of Equity
Consolidated Statements Of Equity (Parenthetical)
Consolidated Statements Of Income
Acquisitions And Divestitures
Acquisitions And Divestitures (Details)
Basis Of Presentation
Benefit Plans
Benefit Plans (Details)
Benefit Plans (Tables)
Benefit Plans Changes In Projected Benefit Obligations, Fair Value Of Plan Assets, And Funded Status Of Plan (Details)
Benefit Plans Schedule Of Allocation Of Plan Assets (Details)
Benefit Plans Schedule Of Assumptions Used (Details)
Benefit Plans Schedule Of Benefit Obligations In Excess Of Fair Value Of Plan Assets (Details)
Benefit Plans Schedule Of Percentage Of Allocation Of Plan Assets Table (Details)
Business Description
Business Description (Details)
Commitments And Contingencies
Commitments And Contingencies (Details)
Commitments And Contingencies - Purchase Commitments (Details)
Earnings Per Share
Earnings Per Share (Details)
Earnings Per Share (Tables)
Financial Instruments
Financial Instruments (Commercial Paper Program And Other Short-Term Borrowings) (Details)
Financial Instruments (Credit Facilities) (Details)
Financial Instruments (Derivative Notional Amounts) (Details)
Financial Instruments (Fair Value Of Debt) (Details)
Financial Instruments (Fair Value Of Derivative Instruments) (Details)
Financial Instruments (Foreign Exchange Risk) (Details)
Financial Instruments (Interest Expense) (Details)
Financial Instruments (Interest Rate Risk) (Details)
Financial Instruments (Long-Term Debt Maturity) (Details)
Financial Instruments (Schedule Of Long-Term Debt) (Details)
Financial Instruments (Senior Notes And Other Long-Term Debt) (Details)
Financial Instruments (Tables)
Goodwill And Other Intangible Assets
Goodwill And Other Intangible Assets (Finite-Lived And Indefinite-Lived Intangible Assets) (Details)
Goodwill And Other Intangible Assets (Goodwill) (Details)
Goodwill And Other Intangible Assets (Narrative) (Details)
Goodwill And Other Intangible Assets (Tables)
Inventories
Inventories (Details)
Inventories (Tables)
Leases
Leases (Details)
Leases (Tables)
Other (Income)/Deductions - Net
Other (Income)/Deductions - Net Other (Income)/Deductions - Net (Details)
Other (Income)/Deductions - Net Other (Income)/Deductions - Net (Tables)
Property, Plant And Equipment
Property, Plant And Equipment (Details)
Property, Plant And Equipment (Tables)
Restructuring Charges And Other Costs Associated With Acquisitions And Cost-Reduction/Productivity Initiatives
Restructuring Charges And Other Costs Associated With Acquisitions And Cost-Reduction/Productivity Initiatives (Tables)
Restructuring Charges And Other Costs Associated With Acquisitions And Cost-Reduction/Productivity Initiatives - Components Of Costs Incurred (Details)
Restructuring Charges And Other Costs Associated With Acquisitions And Cost-Reduction/Productivity Initiatives - Restructuring Benefits And Charges (Details)
Revenue
Revenue (Tables)
Revenue - Other Revenue Information (Details)
Revenue - Revenue By Geographic Area (Details)
Revenue - Revenue By Major Species (Details)
Revenue - Revenue By Product (Details)
Revenue - Revenue By Species (Details)
Schedule Ii - Valuation And Qualifying Accounts
Schedule Ii - Valuation And Qualifying Accounts (Details)
Segment Information
Segment Information (Details)
Segment Information (Tables)
Segment Information - Income Statement (Details)
Segment Information - Income Statement Narrative (Details)
Selected Quarterly Financial Data (Unaudited) (Details)
Share-Based Payments
Share-Based Payments (Components Of Share-Based Compensation Expense) (Details)
Share-Based Payments (Narrative) (Details)
Share-Based Payments (Nonvested Restricted Stock Activity) (Details)
Share-Based Payments (Performance Share Awards (Psas) Activity) (Details)
Share-Based Payments (Stock Option Activity) (Details)
Share-Based Payments (Stock Option Valuation Assumptions) (Details)
Share-Based Payments (Tables)
Significant Accounting Policies
Significant Accounting Policies (Details)
Significant Accounting Policies (Policies)
Stockholders' Equity
Stockholders' Equity (Tables)
Stockholders' Equity - Accumulated Other Comprehensive Income/ (Loss) (Details)
Stockholders' Equity - Changes In Common Shares And Treasury Stock (Details)
Tax Matters
Tax Matters (Deferred Taxes) (Details)
Tax Matters (Tables)
Tax Matters (Tax Contingencies) (Details)
Tax Matters (Taxes On Income) (Details)
Tax Matters Accounting Policy (Policies)
Ticker: ZTS
CIK: 1555280
Form Type: 10-K Annual Report
Accession Number: 0001555280-22-000078
Submitted to the SEC: Tue Feb 15 2022 3:20:21 PM EST
Accepted by the SEC: Tue Feb 15 2022
Period: Friday, December 31, 2021
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/zts/0001555280-22-000078.htm